Cytokine · 2012
Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tomčík Michal, Arima Kazuhiko, Hulejová Hana, Kuklová Markéta, Filková Mária, Braun Martin, Beláček Jaromír, Novák Marek, Bečvář Radim, Vencovský Jiří, Haluzík Martin, Gay Steffen, Müller-Ladner Ulf, Distler Oliver, Senolt Ladislav
Аннотация
OBJECTIVES: Adiponectin was initially described as a regulator of metabolic homeostases. Further studies demonstrated its involvement in the regulation of inflammatory diseases, particularly rheumatic and vascular diseases and some fibrotic processes. The aim of this study was to evaluate adiponectin in the circulation of patients with systemic sclerosis (SSc) and characterise its potential association with skin changes and SSc-related features.
METHODS: Serum levels of adiponectin, interleukin-6 and soluble receptor for interleukin-2 (by ELISA), lipid levels, CRP (by turbidimetry), ANA (by immunofluorescence), autoantibodies of the ENA complex (by immunoblot) and urine levels of pyridinoline and deoxypyridinoline (by HPLC) were measured in 39 patients with SSc, and adiponectin levels were determined in 30 healthy controls matched by age, sex, and body mass index (BMI). Organ manifestations were recorded and skin changes were assessed using the modified Rodnan skin score.
RESULTS: Adiponectin serum levels were similar between patients with SSc and healthy controls (median (IQR), 6.9 (5.9-9.1) vs. 7.8 (6.2-9.5)μg/ml, p=0.670). Levels of serum (ln) adiponectin were negatively correlated with the skin score (r=-0.379, p=0.017). Regression analysis of the relationship between adiponectin and markers of interest provided two statistically significant models: A- with explanatory variables HDL-cholesterol, skin score, disease duration, age (R(2)=0.580); and B- with CRP, skin score, age (R(2)=0.550); in order of a decreasing influence.
CONCLUSION: Based on the results of this study, it might be speculated that adiponectin plays a protective role in skin- and atherosclerosis-related changes during SSc.
METHODS: Serum levels of adiponectin, interleukin-6 and soluble receptor for interleukin-2 (by ELISA), lipid levels, CRP (by turbidimetry), ANA (by immunofluorescence), autoantibodies of the ENA complex (by immunoblot) and urine levels of pyridinoline and deoxypyridinoline (by HPLC) were measured in 39 patients with SSc, and adiponectin levels were determined in 30 healthy controls matched by age, sex, and body mass index (BMI). Organ manifestations were recorded and skin changes were assessed using the modified Rodnan skin score.
RESULTS: Adiponectin serum levels were similar between patients with SSc and healthy controls (median (IQR), 6.9 (5.9-9.1) vs. 7.8 (6.2-9.5)μg/ml, p=0.670). Levels of serum (ln) adiponectin were negatively correlated with the skin score (r=-0.379, p=0.017). Regression analysis of the relationship between adiponectin and markers of interest provided two statistically significant models: A- with explanatory variables HDL-cholesterol, skin score, disease duration, age (R(2)=0.580); and B- with CRP, skin score, age (R(2)=0.550); in order of a decreasing influence.
CONCLUSION: Based on the results of this study, it might be speculated that adiponectin plays a protective role in skin- and atherosclerosis-related changes during SSc.